. . . and, they expect a secondary wave.
Sermo is a global Doctors’ forum site, which allows building of a global consensus of Physicians. As a part of its efforts, it has had a “statistically significant” survey of over 6,000 doctors, regarding Covid-19. Excerpting the just linked report:
Largest Statistically Significant Study by 6,200 Multi-Country Physicians on COVID-19 Uncovers Treatment Patterns and Puts Pandemic in Context
April 2, 2020
Sermo Reports on Hydroxychloroquine Efficacy, Rise in Prophylaxis Use; Over 80% Expect 2nd Outbreak
New York, New York – April 2, 2020 – Widespread confusion, conflicting reports, inconsistent testing, and off-indication use of existing and experimental drugs has resulted in no single source of information from the frontlines. To create a centralized and dynamic knowledge base, Sermo, the largest healthcare data collection company and global social platform for physicians, leveraged its capabilities to publish results of a COVID-19 study with more than 6,200 physicians in 30 countries. The study was completed in three days. Data covers current treatment and prophylaxis options, timing to the outbreak peak, effectiveness of government responses, and much more. Results of the first wave can be found at sermo.com . . . .
Key findings; Sermo Real Time Barometer*:
Treatments & Efficacy
The three most commonly prescribed treatments amongst COVID-19 treaters are 56% analgesics, 41% Azithromycin, and 33% Hydroxychloroquine
Hydroxychloroquine usage amongst COVID-19 treaters is 72% in Spain, 49% in Italy, 41% in Brazil, 39% in Mexico, 28% in France, 23% in the U.S., 17% in Germany, 16% in Canada, 13% in the UK and 7% in Japan
Hydroxychloroquine was overall chosen as the most effective therapy amongst COVID-19 treaters from a list of 15 options (37% of COVID-19 treaters)
The two most common treatment regimens for Hydroxychloroquine were:
Outside the U.S., Hydroxychloroquine was equally used for diagnosed patients with mild to severe symptoms whereas in the U.S. it was most commonly used for high risk diagnosed patients
Globally, 19% of physicians prescribed or have seen Hydroxychloroquine prophylactically used for high risk patients, and 8% for low risk patients
Second Wave of Outbreak
The second global outbreak is anticipated by 83% of global physicians, 90% of U.S. physicians but only 50% of Chinese physicians . . . .
Peak Timing & Restrictions
In the U.S., 63% of physicians recommend restrictions be lifted six or more weeks from now and 66% believe the peak is at least 3-4 weeks away
Notice, that: ” Hydroxychloroquine was overall chosen as the most effective therapy amongst COVID-19 treaters from a list of 15 options (37% of COVID-19 treaters). “
That is the global report from those who are on the frontlines.
Food for thought, given the aftermath of the second Didier Raoult study. And it certainly fits what we have been hearing from Dr Zelenko et al.
It is time for re-thinking in light of what Dr Zelenko has called “World War III” — it would actually be V BTW, III was obviously the 40-year Cold War and IV the ongoing long term conflict with aggressive Islamism. The rules have to change in light of differing risks and opportunities in the face of a fast moving deadly pandemic. END